Dejex Drug Interactions

Agents that may decrease deferasirox systemic exposure: Deferasirox is UDP-glucuronosyltransferase (UGP) substrate, the concomitant administration of deferasirox and the potent UGT inducer (such as rifampicin, phenytoin, phenobarbital, ritonavir) may result in a decrease in deferasirox efficacy. If deferasirox and a potent UGT inducer are used concomitantly, increases in the dose of deferasirox should be considered based on clinical response to therapy.
Agents that may affected by deferasirox: Interaction with agents metabolized by CYP3A4: The concomitant administration of deferasirox and midazolam (a CYP3A4 substrate) resulted in a decrease of midazolam exposure. Therefore, due to a possible decrease in efficacy, caution should be exercised when deferasirox is combined with substances metabolized through CYP3A4 (e.g., ciclosporin, simvastatin, hormonal contraceptive agents).
Interaction with agents metabolized by CYP2C8: The concomitant administration of deferasirox and the CYP2C8 substrate repaglinide resulted in an increase in repaglinide AUC and Cmax. An interaction between deferasirox and other CYP2C8 substrates like paclitaxel cannot be excluded.
Interaction with agents metabolized by CYP1A2: The concomitant administration of deferasirox and the CYP1A2 substrate theophylline resulted in an increase in theophylline AUC. An interaction between deferasirox and other CYP1A2 substrates may be possible.
Anticipated interactions resulting in a concomitant use not recommended: Concurrent use of aluminum oxide and deferasirox may result in decreased deferasirox effectiveness.
Concomitant administration of deferasirox with drugs that have known ulcerogenic potential, such as NSAIDs, corticosteroids, or oral bisphosphonates, and use of deferasirox in patients receiving anticoagulants may increase the risk of gastrointestinal irritation.